



Lilly Announces Webcast to Provide Alzheimer's Disease Update at AD/PD Conference

February 4, 2021

INDIANAPOLIS, Feb. 4, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will conduct a webcast on Monday, March 15, 2021 to provide an update on its Alzheimer's disease program and discuss results from the Phase 2 TRAILBLAZER-ALZ study for donanemab being presented at the 15th International Conference on Alzheimer's and Parkinson's Diseases (AD/PD). The webcast will begin at 10:30 a.m. Eastern Time.

Investors, media and the general public can access a live webcast of the conference call through a link that will be posted on Lilly's website at <https://investor.lilly.com/webcasts-and-presentations>. A replay will also be available on the website following the conference call.

About Eli Lilly and Company

Lilly is a global healthcare leader that unites caring with discovery to create medicines that make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at www.lilly.com. F-LLY

Refer to: Mark Taylor; mark.taylor@lilly.com; (317) 276-5795 (Media)
Kevin Hern; hern_kevin_r@lilly.com; (317) 277-1838 (Investors)



 View original content to download multimedia: <http://www.prnewswire.com/news-releases/lilly-announces-webcast-to-provide-alzheimers-disease-update-at-adpd-conference-301222615.html>

SOURCE Eli Lilly and Company